Halogen-Substituted Thyromimetics for Enhanced Brain Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current thyroid hormone analogs for treating demyelinating diseases like multiple sclerosis face limitations due to low brain uptake and reduced receptor activation, with inner ring methyl substitutions in existing thyromimetics showing reduced activity compared to halogen substitutions.
Innovation Solution
Development of new thyroid hormone analogs, such as JD-20 and JD-21, which replace inner ring methyl groups with halogens like bromine or chlorine, improving binding affinity and selectivity by forming dipole-dipole interactions with the TR ligand binding domain, enhancing potency and brain penetration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If inner ring methyl substitutions are used in thyromimetics, then the compound structure is simpler and easier to synthesize, but the receptor activation activity is reduced
Solution Approach 1:
The patent applies parameter changes by substituting the inner ring methyl groups with halogen atoms (bromine or chlorine). This chemical parameter modification transforms the compound from having reduced activity (methyl substitution) to having enhanced activity (halogen substitution), while maintaining the overall molecular framework and synthetic approach. The halogen substitution specifically improves binding affinity to the TR ligand binding domain through dipole-dipole interactions.
2Reliability
If thyroid hormone analogs are used to treat demyelinating diseases, then remyelination can be stimulated, but brain uptake is limited and cardiotoxicity may occur
Solution Approach 1:
The patent applies local quality by introducing halogen substitutions at specific positions (inner ring) of the thyromimetic molecule. This localized modification enhances brain penetration and TRβ-selectivity without affecting other parts of the molecule that might be responsible for cardiac side effects. The selective enhancement of desired properties (brain uptake, remyelination) while maintaining or reducing unwanted properties (cardiotoxicity) exemplifies the local quality principle.
Solution Approach 2:
The patent modifies the chemical parameters of the thyromimetic by replacing methyl groups with halogens, which changes the molecular properties to improve brain penetration and receptor selectivity. This parameter change allows the compound to achieve better therapeutic efficacy with potentially reduced off-target effects.
3Reliability
If GC-1 is used as a thyromimetic, then TRβ-selectivity is achieved, but potency and brain uptake are reduced
Solution Approach 1:
The patent directly addresses the potency limitation of GC-1 by changing the chemical parameter of the inner ring substitution from methyl to halogen (bromine or chlorine). This modification enhances the binding affinity to the TR ligand binding domain through dipole-dipole interactions, thereby increasing potency while preserving the TRβ-selectivity that was established by GC-1's overall molecular structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
JD-20 and JD-21 demonstrate improved potency and brain uptake compared to their parent compound GC-1, with JD-21 showing significantly greater induction of Hairless gene expression, suggesting enhanced efficacy in treating demyelinating diseases by maintaining critical properties of GC-1 while improving TRβ-selectivity and CNS penetration.
Implementation Method 1
improving binding affinity and selectivity by forming dipole-dipole interactions with the TR ligand binding domain
Data Source
AI summary
Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.